Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Teriparatide (Forteo) Peptide
Recombinant PTH(1-34) for severe osteoporosis.
What is Teriparatide (Forteo)?
Teriparatide (Forteo) is a parathyroid hormone · anabolic bone peptide studied for postmenopausal osteoporosis and male osteoporosis. Below is an educational overview of Teriparatide (Forteo) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Forteo
Osteoporosis in postmenopausal women and men at high fracture risk; glucocorticoid-induced osteoporosis.
A daily injection of an active fragment of parathyroid hormone that builds new bone (bone formation > breakdown).
Possible osteosarcoma risk in rodents — lifetime use limited to 2 years.
- •Nausea
- •Dizziness
- •Leg cramps
- •Joint pain
- •Orthostatic hypotension after first doses
- •High blood calcium
- •Kidney stones
- •Theoretical osteosarcoma risk
- •Prior radiation to bone
- •Paget's disease
- •Unexplained alkaline phosphatase elevation
- •Bone metastases or hypercalcemia
- •Pediatric patients with open epiphyses
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Teriparatide (Forteo) Mechanism of Action
Recombinant fragment of parathyroid hormone (amino acids 1–34). Intermittent dosing stimulates osteoblast activity more than osteoclasts, producing net bone formation and increased bone mineral density.
Teriparatide (Forteo) Research Areas & Benefits
Teriparatide (Forteo) Dosage & Common Research Protocols
20 mcg SC once daily for up to 2 years.
Protocols summarized for educational reference from published research. Not dosing guidance.
Teriparatide (Forteo) Studies & Cited Research
Fracture Prevention Trial
Reduced vertebral fractures by 65% in postmenopausal women.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Teriparatide (Forteo) Side Effects & Safety Considerations
- •FDA-approved.
- •Lifetime use limited to 2 years; transient hypercalcemia possible.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.